Ambalal Sarabhai Enterprises Ltd

AMBASARABH06 Dec 2024

Pharmaceuticals

₹

+0.38 (+0.66%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd

Pharmaceuticals

AMBASARABH06 Dec 2024

₹

+0.38 (+0.66%)

OverviewFundamentals

Corporate action

Peer comparison

Cash flow

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
04-Nov-2024	BC	AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve Unaudited Financial Results (	12-Nov-2024
01-Aug-2024	BC	AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Unaudited Financial Results (	09-Aug-2024
24-May-2024	BC	Approval of Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2024.	26-Jul-2024
24-May-2024	BC	The 46 Annual General Meeting ('AGM') of the Company will be held on Saturday, 29 June, 2024 through Video Conferencing (VC) /Other Audio- Visual Means (OAVM). Pursuant to Regulation 30 of SEBI (L	29-Jun-2024
29-Jun-2024	BC	Mr. Navinchandra Patel, CFO of the Company has resigned from the Company w.e.f. 29.06.2024 after closure of office hours. Please take the same on your records.	29-Jun-2024

No Rights has been declared by AMBASARABH

Book Closure

Record Date	Split Date	Purpose
12-Nov-2024	-	AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve Unaudited Financial Results (
09-Aug-2024	-	AMBALAL SARABHAI ENTERPRISES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve Unaudited Financial Results (
26-Jul-2024	-	Approval of Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2024.
29-Jun-2024	-	The 46 Annual General Meeting ('AGM') of the Company will be held on Saturday, 29 June, 2024 through Video Conferencing (VC) /Other Audio- Visual Means (OAVM). Pursuant to Regulation 30 of SEBI (L
29-Jun-2024	-	Mr. Navinchandra Patel, CFO of the Company has resigned from the Company w.e.f. 29.06.2024 after closure of office hours. Please take the same on your records.

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Ambalal Sarabhai Enterprises Ltd ₹58.37(+0.38/0.66%)	58.37	+0.38	447.31	43.06	50.76	9.93
Astrazeneca Pharma India Ltd ₹6,632.55(+2.00/0.03%)	6,632.55	+2.00	16,581.38	37.91	128.81	24.41
Abbott India Ltd ₹29,053.50(+29.75/0.10%)	29,053.50	+29.75	61,738.69	25.91	48.06	17.53
Cipla Ltd ₹1,477.60(-21.30/-1.42%)	1,477.60	-21.30	119,332.82	22.57	28.19	4.10
Amrutanjan Health Care Ltd ₹722.80(-15.20/-2.06%)	722.80	-15.20	2,089.66	21.23	43.97	7.02
Bliss GVS Pharma Ltd ₹157.90(-2.90/-1.80%)	157.90	-2.90	1,663.19	18.28	20.59	1.62

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Cash and Cash Equivalents at Beginning of the year	0.17	1.80	5.27	0.25	0.28
Net Cash from Operating Activities	-3.82	1.52	-7.79	-10.42	-4.53
Net Cash Used In Investing Activities	3.48	0.61	20.77	15.76	4.92
Net Cash Used In Financing Activities	0.30	-3.76	-16.46	-0.32	-0.42
Net Inc./Dec In Cash And Cash Equivalents	-0.04	-1.63	-3.47	5.02	-0.03
Cash And Cash Equivalents At End Of The Year	0.13	0.17	1.80	5.27	0.25

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

31.35%

FII Shareholding

0.00%

DII Shareholding

0.01%

Public Shareholding

68.65%

**Promoter pledged shareholding 31.35%

About Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 447.31 crores. It has reported a sales of Rs. 0 crores and a net profit of Rs. 4.31 crores for the quarter ended December 2018. The company management includes Kartikeya V Sarabhai, Kartikeya V Sarabhai,Chaula Shastri,Damodar Sejpal,Mayur K Swedia,BRIJESH KHANDELWAL,Govindprasad Namdeo,Ajay Mayor,Bharatendu Jani,Mohal Kartikeya Sarabhai,Pushpa Robin,Satyen Dave (Ambalal Sarabhai Enterprises Ltd) among others.

Chairman

Kartikeya V Sarabhai

Registered office

Shanti Sadan,Mirzapur Road,Ahmedabad,Gujarat,380001

FAX :91-79-25507483

Background

Incorporation Year1977

Face Value₹10

Market Lot1